Fundz

Cabaletta Bio, Inc. reported raising $38.3 Million in an initial SEC Form D filing

PUBLIC · CABADec 10, 2018

Amount Raised

$38.3 Million

$38.3 Million sold, per SEC Form D (first sale Dec 10, 2018)

Round Type

Venture

PhiladelphiaBiotechnologyHealth CareTherapeutics

Who to call at Cabaletta Bio, and when

A new round usually means Cabaletta Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Cabaletta Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Cabaletta Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Cabaletta Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Cabaletta Bio

Location

Philadelphia, Pennsylvania, United States

About

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Cabaletta Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts4 people are listed at Cabaletta Bio. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Cabaletta Bio's next move

See what Strategic adds

Cabaletta Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.